Rani Therapeutics Holdings Inc Class A RANI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.40
- Day Range
- $5.28–5.80
- 52-Week Range
- $1.82–5.80
- Bid/Ask
- $5.50 / $9.21
- Market Cap
- $150.00 Mil
- Volume/Avg
- 220,362 / 94,761
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 163
- Website
- https://www.ranitherapeutics.com
Comparables
Valuation
|
Metric
|
RANI
|
CRNX
|
PMVP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.42 | 5.80 | 0.34 |
Price/Sales | — | 664.21 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RANI
CRNX
PMVP
Financial Strength
|
Metric
|
RANI
|
CRNX
|
PMVP
|
|---|---|---|---|
Quick Ratio | 6.08 | 12.92 | 14.47 |
Current Ratio | 6.36 | 13.07 | 14.78 |
Interest Coverage | −13.00 | — | — |
Quick Ratio
RANI
CRNX
PMVP
Profitability
|
Metric
|
RANI
|
CRNX
|
PMVP
|
|---|---|---|---|
Return on Assets (Normalized) | −58.70% | −38.81% | −23.12% |
Return on Equity (Normalized) | −200.16% | −44.79% | −25.57% |
Return on Invested Capital (Normalized) | −59.50% | −45.62% | −27.79% |
Return on Assets
RANI
CRNX
PMVP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pwrsdtxps | Wnh | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kmcbwzb | Wkznm | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cfkvlwhv | Szcvhh | $98.6 Bil | |
MRNA
| Moderna Inc | Pmzsnndp | Cyjf | $41.0 Bil | |
ARGX
| argenx SE ADR | Rphrtkcx | Vfrrb | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Psmkcjqt | Xhdk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gyzztkpkh | Tbgwqx | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Flkqpfzc | Znrzyg | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mnwctxmkmm | Sgfbnh | $12.6 Bil | |
INCY
| Incyte Corp | Mzxkhtbqz | Vdkmnc | $12.0 Bil |